Evidence map›Paper›PMID 21326105›Full record

ArticleJournal of cardiovascular pharmacology2011

Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat.

Sarah H Lindsey, Kyle A Carver, Eric R Prossnitz, Mark C Chappell

Open access · greenAbstract read
In one paragraph

Article in Journal of cardiovascular pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 106 citations in OpenAlex.

  1. Review
  2. Article
  3. GPER1 activation regulates renal purinergic P2YAmerican journal of physiology. Regulatory, integrative and comparative physiology · 2026
    Article
  4. Article
  5. GPER expression prevents estrogen-induced urinary retention in obese mice.The Journal of steroid biochemistry and molecular biology · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. G protein-coupled estrogen receptor 1 as a novel regulator of blood pressure.American journal of physiology. Renal physiology · 2020
    Review
  17. Estrogen Receptors and Estrogen-Induced Uterine Vasodilation in Pregnancy.International journal of molecular sciences · 2020
    Review
  18. Article
  19. Article
  20. Female Heart Health: Is GPER the Missing Link?Frontiers in endocrinology · 2019
    Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sarah H LindseyThe Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1032, USA. salindse@wfubmc.edu
Kyle A Carver
Eric R Prossnitz
Mark C Chappell
Wake Forest University · US

Funding

Vaso-Hormonal Mechanisms in HypertensionP01HL051952 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GROBAN, LEANNE · 1994 to 2019
$34.8M
Development of GPR30-Selective LigandsR01CA127731 · NCI · UNIVERSITY OF NEW MEXICO · PI ARTERBURN, JEFFREY B, OPREA, TUDOR I · 2008 to 2012
$1.7M
Estrogen, ACE2 and Salt-SensitivityR01HL056973 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CHAPPELL, MARK C · 2004 to 2008
$1.6M
Vascular Interactions of Estrogen Receptor GPR30 and the Renin-Angiotensin SystemK99HL103974 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LINDSEY, SARAH H. · 2011 to 2011
$97k
REGULATION AND FUNCTION OF ANGIOTENSIN (1-7)R29HL056973 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CHAPPELL, MARK C · 1996 to 1999
–
NCI NIH HHS CA-127731NCI NIH HHS R01 CA127731NHLBI NIH HHS HL-51952NHLBI NIH HHS HL-56973NHLBI NIH HHS K99 HL103974NHLBI NIH HHS P01 HL051952NHLBI NIH HHS R01 HL056973NHLBI NIH HHS R29 HL056973NIMHD NIH HHS L60 MD003134
6 · The paper itself

Abstract

Our studies in the mRen2.Lewis female rat, an angiotensin II- and estrogen-dependent model of hypertension, revealed that chronic activation of estrogen receptor GPR30 markedly reduces blood pressure in ovariectomized females. The present studies measured acute vasodilation to the selective GPR30 agonist G-1 and 17-β-estradiol (10(-9)-10(-5.5) M) in isolated aortic rings and mesenteric arteries from intact mRen2.Lewis females. Maximal relaxation was greater in mesenteric vessels versus the aorta for both G-1 (47% ± 8% vs 80% ± 5% of phenylephrine preconstriction, P < 0.001) and estradiol (42% ± 7% vs 83% ± 4% of phenylephrine preconstriction, P < 0.001). The GPR30 antagonist G15 attenuated the response to both estradiol and G-1. Removal of the endothelium or pretreatment with Nitro-L-arginine methyl ester (L-NAME) partially attenuated vasorelaxation. Responses were not altered in mesenteric vessels from ovariectomized females. Immunohistochemical analysis revealed GPR30 expression in mesenteric endothelial and smooth muscle cells, and smooth muscle expression was confirmed in cultured cells. We conclude that estradiol-induced relaxation in conduit and resistance vessels from mRen2.Lewis females may be mediated by the novel estrogen receptor GPR30. The direct vasodilatory response of G-1 in resistance vessels presents one mechanism for the reduction in blood pressure induced by chronic G-1 administration.

Indexed as

HypertensionAnimalsAortaBlood PressureCyclopentanesEndothelial CellsEndothelium, VascularEstradiolFemaleImmunohistochemistryIn Vitro TechniquesMesenteric ArteriesMuscle, Smooth, VascularOvariectomyQuinolinesRats1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanoneCyclopentanesEstradiolGper1 protein, ratQuinolinesReceptors, G-Protein-Coupled

Identifiers

PMID21326105
PMCPMC3095760
OpenAlexW2085814830

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.